Attached files
file | filename |
---|---|
8-K - FORM 8-K - Cellectar Biosciences, Inc. | v468515_8k.htm |
Exhibit 99.1
Cellectar Biosciences to Present at the 2017 Marcum MicroCap Conference
Madison,
Wisc., (June 6, 2017) -- Cellectar Biosciences (Nasdaq: CLRB), an oncology-focused
biotechnology company, today announced that president and CEO Jim Caruso will be presenting at 2017 Marcum MicroCap Conference
on Thursday, June 15 at 11:00 AM ET. The conference will be held June 15-16 at the Grand Hyatt Hotel in New York City.
The company’s presentation will also be webcast at http://wsw.com/webcast/marcum5/clrb,
and will be posted on the company’s website following the conference.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse
oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary
phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range
of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company's
lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated
under an orphan drug designated Phase 1 clinical study in patients with relapsed or refractory multiple myeloma. In addition,
the company has initiated a Phase 2 clinical study to assess efficacy in a range of B-cell malignancies. The company is also developing
PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1602-PTX), a preclinical stage product candidate, and
plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information
please visit www.cellectar.com.
# # #
Contact:
Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com